Fennec Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Fennec Pharmaceuticals (FENC).

Price Target Range — 10 Quarters

Analyst Consensus — 5 Analysts

5Buy

Consensus RatingBuy# Analysts5Avg. Consensus PT$16Upside to Avg. PT+55.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 9, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$16
Aug 12, 2026	B. Riley Securities	Madison El-Saadi	PT Raise	Buy	$16→$18
Aug 12, 2026	Wedbush	David Nierengarten	PT Raise	Outperform	$13→$16
May 22, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$13→$16
Apr 16, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$13
Jan 9, 2026	Piper Sandler	David Amsellem	Initiate	Overweight	$18
Aug 21, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$13
Aug 15, 2025	Craig-Hallum	Chase Knickerbocker	PT Raise	Buy	$13→$14
May 20, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$13
May 14, 2025	Craig-Hallum	Chase Knickerbocker	PT Raise	Buy	$12→$13
Mar 11, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$13
Dec 17, 2024	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$13
Aug 22, 2024	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Buy	$15→$13
Aug 14, 2024	Craig-Hallum	Chase Knickerbocker	PT Cut	Buy	$17→$15
May 15, 2024	Craig-Hallum	Chase Knickerbocker	PT Cut	Buy	$20→$17
May 15, 2024	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Buy	$18→$15
Apr 4, 2024	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$17→$18
Mar 18, 2024	Craig-Hallum	Chase Knickerbocker	PT Raise	Buy	$17→$18

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Fennec Pharmaceuticals, Maintains $16 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and maintains $16 price target.

Benzinga Newsdesk

PRO
B. Riley Securities Reiterates Buy on Fennec Pharmaceuticals, Raises Price Target to $18

B. Riley Securities analyst Madison El-Saadi reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and raises the price target from $16 to $18.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Fennec Pharmaceuticals, Raises Price Target to $16

Wedbush analyst David Nierengarten maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Outperform and raises the price target from $13 to $16.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Fennec Pharmaceuticals, Raises Price Target to $16

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and raises the price target from $13 to $16.

Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Fennec Pharmaceuticals, Maintains $13 Price Target

Wedbush analyst David Nierengarten reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Outperform and maintains $13 price target.

Benzinga Newsdesk

Fennec Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Fennec Pharmaceuticals (FENC) to release Q4 earnings on March 24. Analysts expect EPS of $0.04 and revenue of $14.73 million. Stock gained 1.8% on Monday.

Avi Kapoor

Fennec Pharmaceuticals Inc

Fennec Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Fennec Pharmaceuticals, Maintains $16 Price Target

PRO
B. Riley Securities Reiterates Buy on Fennec Pharmaceuticals, Raises Price Target to $18

PRO
Wedbush Maintains Outperform on Fennec Pharmaceuticals, Raises Price Target to $16

PRO
HC Wainwright & Co. Maintains Buy on Fennec Pharmaceuticals, Raises Price Target to $16

PRO
Wedbush Reiterates Outperform on Fennec Pharmaceuticals, Maintains $13 Price Target

Fennec Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

People Also Watch

People Also Watch

Fennec Pharmaceuticals Inc

Fennec Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Fennec Pharmaceuticals, Maintains $16 Price Target

PROB. Riley Securities Reiterates Buy on Fennec Pharmaceuticals, Raises Price Target to $18

PROWedbush Maintains Outperform on Fennec Pharmaceuticals, Raises Price Target to $16

PROHC Wainwright & Co. Maintains Buy on Fennec Pharmaceuticals, Raises Price Target to $16

PROWedbush Reiterates Outperform on Fennec Pharmaceuticals, Maintains $13 Price Target

Fennec Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Reiterates Buy on Fennec Pharmaceuticals, Maintains $16 Price Target

PRO
B. Riley Securities Reiterates Buy on Fennec Pharmaceuticals, Raises Price Target to $18

PRO
Wedbush Maintains Outperform on Fennec Pharmaceuticals, Raises Price Target to $16

PRO
HC Wainwright & Co. Maintains Buy on Fennec Pharmaceuticals, Raises Price Target to $16

PRO
Wedbush Reiterates Outperform on Fennec Pharmaceuticals, Maintains $13 Price Target